Wave Life Sciences .(WVE)
搜索文档
Wave Life Sciences .(WVE) - 2023 Q4 - Annual Report
2024-03-06 20:55
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37627 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 98-1356880 (State or other jurisdiction of i ...
Wave Life Sciences .(WVE) - 2023 Q4 - Annual Results
2024-03-06 20:39
Exhibit 99.1 Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and every-six-month or annual subcutaneous dosing; clinical trial initiation expected 1Q 2025 Dose escalation ongoing in RestorAATion-1 clinical trial of WVE-006, industry’s first-ever RNA editing candi ...
Wave Life Sciences .(WVE) - 2023 Q3 - Earnings Call Transcript
2023-11-11 01:04
Wave Life Sciences Ltd. (NASDAQ:WVE) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Steve Seedhouse - Raymond James Salim Syed - Mizuho Joseph Schwartz - Leerink Partners Eun Yang - Jefferies Operator Good morning and welcome to Wave Life ...
Wave Life Sciences .(WVE) - 2023 Q3 - Quarterly Report
2023-11-09 20:55
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37627 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 98-1356880 (State ...
Wave Life Sciences .(WVE) - 2023 Q2 - Earnings Call Transcript
2023-08-06 15:14
Wave Life Sciences Ltd. (NASDAQ:WVE) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President and Chief Executive Officer Anne Cheung - Chief Development Officer Kyle Moran - CFO Conference Call Participants Steven Seedhouse - Raymond James Julian Pino - Stifel Eun Yang - Jefferies Salim Syed - Mizuho Operator Good morning, and welcome to the Wave Life Sciences Second Quarter 2023 Financial Results Conference Call. [Opera ...
Wave Life Sciences .(WVE) - 2023 Q2 - Quarterly Report
2023-08-03 19:56
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37627 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 98-1356880 (State or o ...
Wave Life Sciences .(WVE) - 2023 Q1 - Earnings Call Transcript
2023-05-04 01:48
Wave Life Sciences Ltd. (NASDAQ:WVE) Q1 2023 Earnings Conference Call May 3, 2023 8:30 AM ET Company Participants Kate Rausch - VP, IR and Corporate Affairs Paul Bolno - President and CEO Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - CFO Conference Call Participants Mike Linden - Mizuho Joon Lee - Truist Securities Mani Foroohar - SVB Securities Lisa Walter - RBC Operator Good morning, and welcome to the Wave Life Sciences First Quarter 2023 Earnings Call. [Operator Instructions] As a r ...
Wave Life Sciences .(WVE) - 2023 Q1 - Quarterly Report
2023-05-03 19:55
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37627 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 98-1356880 (State or ...
Wave Life Sciences .(WVE) - 2022 Q4 - Annual Report
2023-03-23 19:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37627 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 98-1356880 (State or other jurisdiction of i ...
Wave Life Sciences .(WVE) - 2022 Q4 - Earnings Call Transcript
2023-03-22 23:55
Wave Life Sciences Ltd (NASDAQ:WVE) Q4 2022 Earnings Conference Call March 22, 2023 8:30 AM ET Company Participants Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Mike Linden - Mizuho Joon Lee - Truist Securities Julian Pino - Stifel Operator Good morning, and welcome to the Wave Life Sciences Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all particip ...